Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial
1. 请及时下载文件确认是否正确, 系统将在 2026-01-16 15:10:14 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/S2213-2600(25)00121-3
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S2213260025001213
其他信息:
出版社: Elsevier BV
作者: Yuankai Shi; Lin Wu; Yinghua Ji; Gongyan Chen; Baolan Li; Minghong Bi; Runxiang Yang; Liyun Miao; Guojun Zhang; Hongjun Gao; Longhua Sun; Mingjun Zhang; Shundong Cang; Meili Sun; Wenxiu Yao; Zhijie Pan; Jiuwei Cui; Yi Xiao; Qiming Wang; Yongxiang Song; Meiqi Shi; Daqing Wang; Zeng Li; Hailong Liu; Xiaorong Dong; Xiang Wang; Jian Fang; Yanyan Xie; Aimin Zang; Mingwei Chen; Xia Song; Kun Wang; Bi Chen; Qun Chen; Huijuan Wang; Ping Sun; Wei Li; Yanming Zhang; Diansheng Zhong; Xuezhi Hao; Tong Zhou; Yuansong Bai; Jianhua Shi; Yu Zhang; Jun Li; Yajun Li; Jiawen Xiao; Hongming Pan; Yaning Zhao; Hong Lu; Mei Yin; Hongyu Chen; Tingting Song; Xuyu Wei
